DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR CADUET
All Clinical Trials for Caduet
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00150384 | Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population | Completed | Pfizer | Phase 4 | 2004-07-01 | The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population |
| NCT00332761 | Caduet in an Untreated Subject Population | Completed | Pfizer | Phase 4 | 2006-06-01 | The purpose of this study is to determine if Caduet will lower blood pressure to <140/90 mmHg and lower LDL Cholesterol to <100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions. |
| NCT00407537 | Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors | Completed | Pfizer | Phase 4 | 2007-03-01 | To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors. |
| NCT00412113 | A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk | Completed | Pfizer | Phase 4 | 2007-01-01 | The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood pressure and low density lipoprotein cholesterol (LDL-C) goals compared with a Joint National Committee 7/ National Cholesterol Education Program Adult Treatment Panel III (JNC 7/NCEP ATP III) guideline-based approach (Norvasc plus TLC regimen) after 6 weeks of treatment in primary prevention subjects with hypertension and additional risk factors, including dyslipidemia. |
| NCT00579254 | Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors | Terminated | Pfizer | Phase 4 | 2007-12-01 | To assess the effect of single pill therapy on the management of hypertension and other cardiovascular risk factors (e.g., dyslipidemia) in Indian patients in whom the treating doctor has already considered that the administration of the amlodipine/atorvastatin single pill to be appropriate |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Caduet
Condition Name
Clinical Trial Locations for Caduet
Trials by Country
Clinical Trial Progress for Caduet
Clinical Trial Phase
Clinical Trial Sponsors for Caduet
Sponsor Name
